# Defining the normal: new approaches for harmonized subset definitions and gating procedures

Ester Mejstříková, Veronika Kanderová CLIP Cytometry Department of Pediatric Hematology and Oncology 2nd Faculty of Medicine University Hospital Motol



#### ESCCA 2023 Utrecht Disclosure commercial conflict of interest

х	No, nothing to disclose
	Yes, as specified below:

# Flow cytometry in immunology and hematology


#### We ask whether the sample is:

- normal (composition of subsets and its phenotype)=diagnosis of primary immunodeficiency (PID)
- reactive (i.e.because of infection)
- abnormal (presence of atypical suspect cells)

Immunology report % and absolute count listed as values and compared with reference ranges

#### Hematology

Identification of populations (normal/abnormal) Commentary almost always available SELECTION OF APPROPRIATE GATE – in PID we focus on CD45++ low Ssc cells



# PID DIAGNOSIS algorithm:

- Clinical examination
- Laboratory investigations
- Analysis of lymphocyte subpopulations
- Frequently we use experience generated in individual single lab

The composition of immune cells is influenced by age


# What should be (ideally) same in sample processing and is distinctly different

- How we gate the cells
- How we define the subset (i.e. plasmablast, RTE)
- What is the normal frequency of rare subsets:  $V\alpha 24V\beta 11$ , TREGs..
- Which antibody clones are used
- Which fluorochromes are used
- How we prepare sample (bulk lysis. stain-lyse-wash)

## Gating strategies

- 2D graph approach = standard in the diagnostic work up
- Backgating strategy
- increasing amount of parameters = becomes impossible to check all 2D combinations of parameters
- Inclusion of bioinformatic tools
- Consider <u>non PID disease</u> (especially haematological malignancy)

## Spectrum of potential clinical diagnoses according age



## Lymphoid organogenesis in mammals


1) genesis of **primary** lymphoid organs: **bone marrow** and **thymus** 

2) development of **secondary** lymphoid organs (SLOs): **lymph nodes**, **Peyer patches** and **spleen** 


3) development of **terciary lymphoid organs** (TLOs): within tissues after the initiation of immune response

 Role of lymphoid tissue inducer (LTi) cells in generation of most SLOs

In imunology, we analyze mostly peripheral blood



#### Severe combined deficiency learns us about normal lymphocyte development



## Dynamics of lymphocyte subsets during aging


 most lymphocytes are naive at birth and have not yet encountered a foreign antigen


 "Redundancy" in production of lymphocytes to increase the probability of succesful elimination of the pathogen

## T cell composition and maturation

Development starts in thymus (almost never available for diagnostic purposes, except for patients undergoing cardiac surgery)

- RTE essential parameter indicating thymic function (defined as CD62L+CD45RO-HLA-DR-<u>CD31</u>+ Kalina et al.)
- population shifts during infection (incease of CD8, HLA DR expression..)
- T-cell activation
- Replicative senescence, and oligoclonal expansions





## **B** cell composition

Maturation starts in bone marrow

At birth mostly naive B cells are present in blood


Categorisation of CVID (based on adult reference ranges its applicability in children is questionable)

Piatosa et al (Clin Cytometry 2010):

- definition of plasmablasts (Piatosa defines them as IgM<sup>neg</sup> CD38<sup>high</sup> in some age subgroups normal values decrease to 0)
- definition of transitional B cells

Duchamp et al.: French reference values, missing info about plasmablasts and transitional B cells


## Bone marrow composition depends on age



Childhood Leukaemia Investigation Prop


Michaela Reiterova

## B cell maturation marrow and blood



#### CD19 positive NK cells

- physiological rare variance, prevalence in healthy individuals unknown
- patient followed after liver transplant, EBV reactivation



#### Brief Communication

Apparent CD19 Expression by Natural Killer Cells: A Potential Confounder for Minimal Residual Disease Detection by Flow Cytometry in B Lymphoblastic Leukemia

Lorinda Soma,<sup>\*</sup> David Wu, Xueyan Chen, Kerstin Edlefsen, Jonathan R. Fromm, and Brent Wood Department of Laboratory Medicine, University of Washington, Seattle, Washington

Cytometry Part B (Clinical Cytometry) 88B:358–360 (2015)

#### Letter to the Editor

NK Cells Expressing the B Cell Antigen CD19: Expanding the Phenotypical Characterization and the Potential Consequences from Misinterpretation of This Subset Population

Korol et al.: 44 cases out of 1002 cases with suspect immunodeficiency analyzed for lymphocyte subpopulations No other B cell specific markers on CD19<sup>pos</sup> NK cells

#### How to read immunological report and what does mean shift from normal

#### Lymphocyte gate

CD19 : ↓ absence BTK deficiency, B- SCID, CVID, B cell targeted therapy, GATA 2def

CD3:  $\downarrow$  T- SCID , immunosuppression, infection (HIV)

CD3neg16.56+:  $\downarrow$  absent in NK- SCID,  $\downarrow$  GATA2def

CD3+ CD4+ CD45RA+ CD27+ (Naive CD4 T): decrease during viral infections, almost absent in SCID

CD3+ CD8+ CD45RA+ CD27+ (Naive CD8 T): decrease during viral infections, almost absent in SCID

CD4 :  $\downarrow$  T- SCID (cave maternofetal engraftment), infection (HIV), immunosuppression

CD8 :  $\downarrow$  T- SCID (cave maternofetal engraftment)

TCR $\gamma\delta$ :  $\uparrow$  some infections (francisella tularensis, EBV), IBD, hypomorphic RAG deficiency, CID

RTE:  $\downarrow$  absent in SCID, decrease after corticosteroids, infection

HLA DR out of CD3+4+ : increased especially in viral infections, HLH

HLA DR out of CD3+8+: increased in viral infections, HLH

## How to read immunological report and what does mean shift from normal

## Gate CD19+

CD27+ Memory: ↓ disturbed peripheral B cell maturation (CVID, corticosteroids, ALPS), ↑ reactive during the infection, GATA2 deficiency

IgD- IgM- CD27+ Class switched: ↓ disturbed peripheral B cell maturation (CVID, corticosteroids, ALPS)


IgD+ CD27+ Marginal zone like: ↓ disturbed peripheral B cell maturation

IgD+ CD27- Naive: ↑ disturbed peripheral B cell maturation (CVID, corticosteroids, ALPS)

CD21low CD38low:  $\uparrow$  autoreactivity, autoimmunity especially in CVID, consider CD19+ NK cells

CD24++ CD38++ CD27- Transitional:  $\downarrow$  B cell suppression in bone marrow

CD38++ CD27++ Plasmablast: ↑ increased during infection (EBV, bacterial), EBV LPD in immune suppressed patients, GATA2 deficiency




## Example of case with suspect SCID

patient (boy) captured by neonatal screening program. T cell excision circles (TRECs are missing)

- diagnosed through newborn screen program (TREC 0. KREC normal range)
- so far no signs of immunodeficiency. no clinical history of immunodeficiency
- in family known methemoglobinemia. abnormal hemoglobin (heterozygous mutation HBB: c.190C>T (His-Tyr). Hb M Saskatoon
- born 22.2.22. first immunological check up 15.03.22
  WBC: 7.5 x10^9/L. LY: 2.680 x10^9/L. identified heterozygous mutation HBB

### Lymphocyte screening tube CD45RA/CD27/CD4/CD19+TCRgd/CD3/CD16/CD8//HLADR/CD45/C D56



no **T cells (<0.1%).** B cells dominate (60% out of lymphocytes) NK cells (35%).


**B** cells are mostly naive 98%. (half are transitional). Marginal zone like 0.9 and switched memory only 0.2%. Plamablasts almost missing (0.02%).

#### **Conclusion: SCID T-B+NK+**


mutation c.353-10C>G (CD3 epsilon)

### suspect CVID (marrow, blood, lung biopsy)

- 10 yrs old boy, failure to thrive, 3 weeks respiratory infection not responding to antibiotics/antimycotics.
  more frequent respiratory infection since early childhood, alopecia spontaneously resolved 2 years ago
- hepatosplenomegaly
- lgG 3.3, lgA 13, lgM 0,27 (g/L)



#### **LUNG** Susp GLILD syndrome



## Example of suspect immunodeficiency

- 01/2022 Boy 9 year old
- Since 02/2021 . repeated infections. recurent fever with unclear focus. fluctuating neutropenia
- Between 07/2021 and 11/2021 clinically doing well
- Autumn 2021 again recurrent fevers

#### Blood count 01/2022


WBC: **1.6 x10^9/I** RBC: 3.97 x10^12/I HGB: 113 g/I HCT: 0.317 l/I MCV: 79.8 fl MCH: 28.5 pg MCHC: 356.5 g/l RDW: 14.7 % PLT: 178 x10^9/l **NEU(Se+T)#: ! 0.469 x10^9/l** 

## **PID panel conclusion:**


 Lymphopenia, % decreased B cells (5.8%), low transitional B cells (0.3%, probably decreased production in bone marrow), no significant T cell activation

## Follow up

 Moderate improvement in blood count parameters within 6 weeks. But still tired, repeatedly subfebrile. During regular check blasts detected on blood smear.



#### Retrospective reanalysis of initial PID panel Lymphocyte screening tube CD45RA/CD27/CD4/CD19+TCRgd/CD3/CD16/CD8//HLADR/CD45/CD56



# Conclusion

- Reference ranges never ending story = we need them not only for accreditation
- Immunology report is a list of values which make complex picture usually about one part of immune system
- Information about patient history is essential but frequently not available
- In routine practise bioinformatic tools would be especially helpful in examination of sample quality, potential role in identification of suspect unexpected population
- In PID algorithm is useful to combine information from the various compartments when the samples are available



CLIP – Childhood Leukemia Investigation Prague Veronika Kanderova Michaela Nováková Barbora Cabalkova Eva Froňková Markéta Kubričanová Žaliová Jan Trka Eva Froňková Tomáš Kalina Ondřej Hrušák



Alberto Orfao Jacques van Dongen Giuseppe Gaipa Vincent van der Velden Miriam van der Burg

DPHO: Lucie Šrámková Jan Starý Martina Suková Petr Smíšek Markéta Racková

#### **Department of Immunology**

Anna Sediva Marketa Bloomfield Adam Klocperk